Eisai Suspends Epilepsy Drug, Fycompa, in Germany

Eisai is to suspend commercial distribution of its new epilepsy drug Fycompa in Germany, noting that they continue to disagree with the country’s reimbursement regulatory body’s rejection of the therapy. In March, the German Federal Joint Committee declared that they consider the additional benefit of Fycompa unproven when compared to two other treatments – GlaxoSmithKline’s

Continue Reading

Pharmaceutical Industry Is Unappreciated By Society

Bayer’s chief executive, Marijn Dekkers (pictured), has expressed concern around the pricing squeeze being placed on innovative pharmaceutical groups, whose efforts, he believes, are greatly under-appreciated by society. Speaking at Bayer’s annual press conference in Leverkusen, Dr Dekkers commented that it is “crucial to have an environment that views innovation as something desirable and values

Continue Reading